中国药房2013，Vol.24Issue(4)：347-349,3.DOI:10.6039/j.issn.1001-0408.2013.04.21
普拉克索联合左旋多巴治疗帕金森病的临床观察
Clinical Observation of Pramipexole Combined with Levodopa for Parkinson's Disease
邓强 1李映会 1覃瑜1
作者信息
- 1. 达州市中心医院神经内科,四川达州635000
- 折叠
摘要
Abstract
OBJECTIVE: To evaluate the therapeutic effect and safety of pramipexole combined with levodopa for Parkinson's disease (PD). METHODS: 80 PD patients were randomly divided into levodopa group and levodopa + pramipexole group with 40 cases in each group. Each group were treated for 12 weeks and evaluated with Unified Parkinson's Disease Rating Scale(UPDRS) and Hamilton Depression Scale(HAMD) at 4, 8 and 12 weeks. TESS Rating Scale was used to evaluate adverse drug reactions 12 weeks after treatment. RESULTS: Compared with the baseline level, UPDRS and HAMD scores were significantly different in 2 groups (P<0.05) at 4, 8 and 12 weeks. The changes of UPDRS I , II , I and HAMD scores to the baseline showed statistical significance between 2 groups (P<0.05). There were no significant difference in TESS Rating Scale between 2 groups (P>0.05). CONCLUSION: Pramipexole can improve clinical symptoms of PD and reduce the incidence of complications effectively, and it is safe and effective.关键词
普拉克索/帕金森病/左旋多巴/临床观察Key words
Pramipexole/Parkinson's disease/Levodopa/Clinical observation分类
医药卫生引用本文复制引用
邓强,李映会,覃瑜..普拉克索联合左旋多巴治疗帕金森病的临床观察[J].中国药房,2013,24(4):347-349,3.
